Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Any Decision About AT&T Stock Should Rely on Prudence, Not Emotion

By Chris Markoch, InvestorPlace Contributor

After AT&T announced a dividend cut, investors may be furious at management. But if you currently own T stock, the prudent decision may be to just sit tight and wait to see what happens next.

The 6 Best Penny Stocks to Buy for September

By Chris Markoch, InvestorPlace Contributor

Investing in penny stocks can be an intriguing numbers game. With many stocks to choose from, a handful are bound to be winners. Here are seven penny stocks that look like good buys in September.

Is the Juice Worth the Squeeze in Clover Health Investments Stock?

By Chris Markoch, InvestorPlace Contributor

CLOV stock looks to be setting up for a short squeeze. But that runs the risk of papering over the obstacles that Clover Health needs to overcome.

Don’t Give In to Temptation in Atossa Therapeutics

By Chris Markoch, InvestorPlace Contributor

Atossa Therapeutics has made a pivot to assist in the battle to fight Covid-19. But it seems that investors in ATOS stock are finding this to be a message they've already heard.

ZOM Stock Is on the Move, but That Doesn’t Make It a Good Play Here

By Chris Markoch, InvestorPlace Contributor

After months of declining, ZOM stock may have found a floor. The question is if that will hold and whether it makes the beleaguered stock a good buy? 

Load More